Literature DB >> 28218823

Review of the Development of Methods for Characterization of Microspheres for Use in Embolotherapy: Translating Bench to Cathlab.

Marcus Caine1,2, Dario Carugo1, Xunli Zhang1, Martyn Hill1, Matthew R Dreher2, Andrew L Lewis2.   

Abstract

Therapeutic embolotherapy is the deliberate occlusion of a blood vessel within the body, which can be for the prevention of internal bleeding, stemming of flow through an arteriovenous malformation, or occlusion of blood vessels feeding a tumor. This is achieved using a wide selection of embolic devices such as balloons, coils, gels, glues, and particles. Particulate embolization is often favored for blocking smaller vessels, particularly within hypervascularized tumors, as they are available in calibrated sizes and can be delivered distally via microcatheters for precise occlusion with associated locoregional drug delivery. Embolic performance has been traditionally evaluated using animal models, but with increasing interest in the 3R's (replacement, reduction, refinement), manufacturers, regulators, and clinicians have shown interest in the development of more sophisticated in vitro methods for evaluation and prediction of in vivo performance. Herein the current progress in developing bespoke techniques incorporating physical handling, fluid dynamics, occlusive behavior, and sustained drug elution kinetics within vascular systems is reviewed. While it is necessary to continue to validate the safety of such devices in vivo, great strides have been made in the development of bench tests that better predict the behavior of these products aligned with the principles of the 3R's.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug-eluting bead; embolization; microsphere; performance testing

Mesh:

Year:  2017        PMID: 28218823     DOI: 10.1002/adhm.201601291

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  8 in total

Review 1.  Emerging Polymer Materials in Trackable Endovascular Embolization and Cell Delivery: From Hype to Hope.

Authors:  Md Mohosin Rana; Marites P Melancon
Journal:  Biomimetics (Basel)       Date:  2022-06-10

2.  A clinical trial of super-stable homogeneous lipiodol-nanoICG formulation-guided precise fluorescent laparoscopic hepatocellular carcinoma resection.

Authors:  Pan He; Yongfu Xiong; Jinfa Ye; Biaoqi Chen; Hongwei Cheng; Hao Liu; Yating Zheng; Chengchao Chu; Jingsong Mao; Aizheng Chen; Yang Zhang; Jingdong Li; Jie Tian; Gang Liu
Journal:  J Nanobiotechnology       Date:  2022-06-03       Impact factor: 9.429

3.  An Injectable Click-Crosslinked Hydrogel that Prolongs Dexamethasone Release from Dexamethasone-Loaded Microspheres.

Authors:  Ji Yeon Heo; Jung Hyun Noh; Seung Hun Park; Yun Bae Ji; Hyeon Jin Ju; Da Yeon Kim; Bong Lee; Moon Suk Kim
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

4.  Evaluation of novel formulations for transarterial chemoembolization: combining elements of Lipiodol emulsions with Drug-eluting Beads.

Authors:  Marcus Caine; Ting Chung; Hugh Kilpatrick; Zainab Bascal; Sean Willis; Yiqing Tang; Thierry de Baere; Matthew Dreher; Andrew Lewis
Journal:  Theranostics       Date:  2019-07-28       Impact factor: 11.556

5.  Immobilized thrombin on X-ray radiopaque polyvinyl alcohol/chitosan embolic microspheres for precise localization and topical blood coagulation.

Authors:  Xiaohong Li; Xiongfa Ji; Kun Chen; Muhammad Wajid Ullah; Basen Li; Jiameng Cao; Lin Xiao; Jun Xiao; Guang Yang
Journal:  Bioact Mater       Date:  2021-01-12

6.  A proof-of-concept study of the in-vivo validation of a computational fluid dynamics model of personalized radioembolization.

Authors:  Raúl Antón; Javier Antoñana; Jorge Aramburu; Ana Ezponda; Elena Prieto; Asier Andonegui; Julio Ortega; Isabel Vivas; Lidia Sancho; Bruno Sangro; José Ignacio Bilbao; Macarena Rodríguez-Fraile
Journal:  Sci Rep       Date:  2021-02-16       Impact factor: 4.379

7.  A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma.

Authors:  Pan He; En Ren; Biaoqi Chen; Hu Chen; Hongwei Cheng; Xing Gao; Xiaoliu Liang; Hao Liu; Jingdong Li; Bo Li; Aizheng Chen; Chengchao Chu; Xiaoyuan Chen; Jingsong Mao; Yang Zhang; Gang Liu
Journal:  Theranostics       Date:  2022-01-24       Impact factor: 11.556

8.  Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma.

Authors:  Marie Vogeler; Isabelle Mohr; Jan Pfeiffenberger; Simon David Sprengel; Miriam Klauss; Boris Radeleff; Andreas Teufel; De-Hua Chang; Christoph Springfeld; Thomas Longerich; Uta Merle; Arianeb Mehrabi; Karl Heinz Weiss; Markus Mieth
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-25       Impact factor: 4.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.